Ironwood Pharmaceuticals, Inc. (IRWD)
Automate Your Wheel Strategy on IRWD
With Tiblio's Option Bot, you can configure your own wheel strategy including IRWD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IRWD
- Rev/Share 1.9735
- Book/Share -2.0752
- PB -0.2932
- Debt/Equity -1.7934
- CurrentRatio 3.3386
- ROIC -0.2602
- MktCap 98467470.0
- FreeCF/Share 0.4871
- PFCF 1.2558
- PE -3.1184
- Debt/Assets 1.8309
- DivYield 0
- ROE 0.0991
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IRWD | Jefferies | Buy | Hold | -- | -- | April 15, 2025 |
| Downgrade | IRWD | Wells Fargo | Overweight | Equal Weight | -- | -- | April 15, 2025 |
| Downgrade | IRWD | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | April 14, 2025 |
| Initiation | IRWD | Leerink Partners | -- | Market Perform | -- | $5 | Sept. 9, 2024 |
News
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Read More
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.
Read More
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st.
Read More
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
Published: April 14, 2025 by: Benzinga
Sentiment: Negative
Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.
Read More
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
Published: April 10, 2025 by: Seeking Alpha
Sentiment: Positive
Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZESS remains the market leader, and Ironwood's restructuring efforts aim to streamline operations and focus on apraglutide. Apraglutide's strong clinical data and potential FDA approval could significantly boost Ironwood's revenue, positioning it as a key player in the SBS market.
Read More
Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
SAN ANTONIO--(BUSINESS WIRE)--Ironwood Midstream Energy Partners III, LLC (Ironwood III) today announced it has secured a substantial equity commitment from Kayne Anderson Energy Infrastructure Fund, Inc. (KYN). Led by industry veteran Mike Williams, Ironwood III has a long-term operating strategy, focused on the acquisition, development, and operation of top-tier midstream assets in the most economic and desirable oil and gas producing regions in the United States. In conjunction with the equi.
Read More
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you work in the biotech industry, you might know the name Alex Denner.
Read More
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Read More
About Ironwood Pharmaceuticals, Inc. (IRWD)
- IPO Date 2010-02-03
- Website https://www.ironwoodpharma.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Thomas A. McCourt
- Employees 253